Regeneron Pharmaceuticals, Inc. REGN NASDAQ

Regeneron Pharmaceuticals, Inc. (REGN) has shown moderate revenue growth over the past 3 years, expanding from $12.2B to $14.3B (average +5.7%/yr). Net income reached $4.5B, reflecting modest earnings improvement at +1.6%/yr on average. The net profit margin is 31.4%, which is exceptional. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 85.4% (high), with a -1.8pp trend over the period. With a $78B market cap and MOAT composite score of 80/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (55/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 36-year history, the company was profitable in 15 of 36 years — a mixed long-term record
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (80/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 83/100 with 6/7 criteria passed.